My continuing work with Parkinson's patients
Throughout my clinical work, I have become increasingly interested in the potential of regenerative medicine and immune regulation for people living with Parkinson's disease. I believe we need to look beyond the symptoms alone and consider the wider biological environment in which neurodegeneration develops.
I have administered mesenchymal stem cells (MSCs) to more than 200 patients with Parkinson's disease. What I have observed has been encouraging enough for me to continue investigating and developing this approach. I have seen changes that give me reason for optimism, although I recognise that individual responses vary and that properly controlled clinical research is still needed to establish the effectiveness and long-term benefits of these treatments.
My approach increasingly combines MSC therapy with GcMAF, alongside a careful assessment of each patient's nutritional status, deficiencies and general health. I am particularly interested in the possibility that supporting the immune environment, reducing inflammatory stress and protecting the surviving nerve cells may offer patients additional opportunities.
Parkinson's affects more than movement
Parkinson's disease is a progressive neurological condition involving the loss or dysfunction of dopamine-producing neurons, particularly in an area of the brain called the substantia nigra. Dopamine is essential for movement, coordination, motivation and several other neurological functions.
As these neurons are damaged or lost, patients can experience tremor, muscle rigidity, slowed movement, balance problems and changes in coordination. But Parkinson's is considerably more than a movement disorder. Patients may also have sleep disturbances, fatigue, constipation, changes in blood pressure, anxiety, depression, cognitive difficulties, speech changes and problems swallowing. Gradually, it can affect almost every part of everyday life.
Something that is frequently overlooked is that Parkinson's affects the entire family. I have seen how hard it is for spouses, children and other relatives to watch someone they love lose their independence: struggling to dress, walk, eat, speak or do things that used to be effortless. Family members often become carers, sometimes without preparation or support. Relationships change, responsibilities grow and the emotional burden can be considerable.
This is why I believe the approach to Parkinson's should look at the whole person, not only the tremor or the difficulty walking. Preserving independence, confidence, communication and quality of life must remain important goals.
Why I am interested in mesenchymal stem cells
Mesenchymal stromal cells (MSCs) are particularly interesting because they release a range of biological signalling molecules. My interest centres on several mechanisms that may be relevant to neurodegenerative conditions.
Modulating neuroinflammation
MSCs release signalling molecules that can influence immune activity. I am particularly interested in their potential to moderate excessive inflammatory responses in the nervous system. Persistent neuroinflammation is one of the processes being investigated in Parkinson's disease.
Releasing neurotrophic factors
MSCs can release growth factors and protective signalling molecules, including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). These molecules are involved in the survival, maintenance and repair of neurons, and may support the environment around the dopamine-producing neurons that remain.
Supporting dopamine-producing neurons
Oxidative stress and inflammation are among the factors associated with neuronal damage in Parkinson's disease. Signals from MSCs seem to help influence some of these processes, potentially supporting the survival of the remaining nerve cells.
Supporting the surrounding tissue
One of the most interesting characteristics of MSCs is how they communicate with surrounding tissue. Rather than thinking of them simply as replacement cells, I consider their paracrine effects: the biological signals they release and how these influence neighbouring cells.
Possible improvements in symptoms
Improvements in motor symptoms, including stiffness, tremor and balance, are important outcomes being investigated in MSC research. However, I do not promise these improvements, and I recognise that responses vary considerably between individuals.
Why I add GcMAF
I have a particular interest in the relationship between immune regulation and neurological health, which is one of the reasons I have incorporated GcMAF into my investigational approach.
GcMAF (Gc protein-derived macrophage activating factor) is an immune-modulating biological preparation. Its effects on macrophages and other immune signalling pathways have long interested me, and its effect in my clinical cases of Parkinson's disease has been very encouraging.
Macrophage and microglial activity
Microglia are specialised immune cells in the central nervous system. They help maintain the neurological environment and respond to cell damage and abnormal protein build-up. I am interested in immune-modulating approaches that support more balanced microglial activity, and the relationship between GcMAF and microglial activation in Parkinson's disease is very encouraging.
Alpha-synuclein and cellular debris
A characteristic feature of Parkinson's disease is the accumulation of abnormal alpha-synuclein proteins, which are associated with Lewy bodies. I am interested in how GcMAF may support the body's normal immune clearance mechanisms and contribute to a healthier cellular environment.
Supporting immune balance
Neurodegenerative conditions involve complex interactions between the nervous and immune systems. I am interested in approaches that support more balanced immune signalling rather than excessive or prolonged inflammation.
How MSCs and GcMAF work together
MSCs release signalling molecules that influence tissue repair and inflammation, while GcMAF influences macrophage activity. These approaches complement one another, and I regard the combination as a synergistic treatment.
Why the combination deserves further investigation
In regenerative medicine, I do not believe we should focus on one biological intervention in isolation. The body is an interconnected system: immune function, nutritional status, metabolic health, inflammation and neurological function are all related.
Combining MSCs and GcMAF addresses different parts of that biological environment at the same time. MSCs provide signalling molecules associated with tissue maintenance and repair, while GcMAF is used to influence immune regulation. My clinical observations have been encouraging enough for me to keep exploring the potential of this combination.
Stem cell quality and donor selection
I place considerable importance on the quality, traceability and testing of the biological material I use. The stem cells undergo rigorous laboratory testing and quality-control procedures, and I consider donor screening, infectious disease testing, cell identity, viability, sterility and proper manufacturing controls essential.
I also apply a donor-selection policy that excludes donors who have received COVID-19 vaccinations. This is a precautionary criterion within my own programme. See the laboratory standards.
Where my GcMAF comes from
The quality and testing of GcMAF preparations are equally important to me. I use GcMAF supplied by DubaiBioremedix.com because of the quality-control and testing procedures behind it.
With any biological preparation, I believe it is essential to understand what is being administered, how it is manufactured, how it is tested and how its quality is maintained throughout manufacturing and handling.
Why blood tests and nutritional status matter
One of the most important parts of my approach is assessing the patient's overall health rather than concentrating only on Parkinson's disease. Identifying and treating nutritional deficiencies and other correctable problems is an important part of good care. I pay particular attention to:
- Vitamin B12 and folate
- Vitamin D
- Iron status and ferritin
- Magnesium
- Thyroid function
- Blood glucose regulation
- Kidney and liver function
- Markers of nutritional status
- Heavy metal toxicity
- Mould toxicity
- Other abnormalities found in individual tests
These results are interpreted in the context of the patient's medical history, medication and condition. Deficiencies, metabolic problems and other untreated issues need to be properly assessed and managed. My aim is to support the patient's general health alongside any regenerative treatment.
Why the stage of the disease matters
I am particularly interested in treating patients in the earlier stages of Parkinson's disease. The reasoning is straightforward: earlier on, patients may still have more working dopamine-producing neurons and neurological pathways, and preserving that remaining function is an important consideration. Patients in earlier stages may have more chance of maintaining independence, although this does not guarantee a better response to MSCs or GcMAF.
I also continue to treat patients with more advanced Parkinson's disease. Even when the disease has progressed considerably, there may still be ways to improve general wellbeing and quality of life, although expectations must be realistic and results may be limited.
I do not consider advanced Parkinson's an automatic reason to abandon hope, but I am equally careful not to promise neurological recovery where extensive loss of neurons has already occurred.
Why I continue this work
Having given MSCs and GcMAF to more than 200 Parkinson's patients, I remain interested in the potential of regenerative medicine and immune modulation. The results I have seen have been encouraging enough for me to continue.
There is much more to learn about how neuroinflammation, immune regulation, cellular signalling and neurological degeneration interact. Combining MSCs with GcMAF, while assessing and correcting each patient's nutritional and metabolic deficiencies, is a more complete approach than relying on a single treatment. I want to keep learning from each patient, documenting outcomes carefully, and improving our understanding of who may benefit, what improvements are possible and what the limitations are.
My message to patients and their families
A Parkinson's diagnosis can be devastating. It changes not only the life of the person diagnosed but also the lives of those closest to them. Families want to know what they can do, whether there are other options worth exploring, and whether their loved one can stay independent for as long as possible.
My advice is always to approach the condition as a whole: understand the patient's nutritional status, investigate deficiencies, monitor general health and continue appropriate neurological care.
I do not believe in giving patients unrealistic promises. I believe in careful assessment, responsible treatment, ongoing observation and the continued pursuit of better outcomes. Above all, patients and their families should not feel forgotten simply because they have been diagnosed with a progressive neurological condition. There is still much to learn, much to investigate and much to do.
Dr. Fermín Celma. Please share this information to help raise awareness.
Copyright Maryjayne Aria, author of Immune Health, Terrain and GcMAF. Read more on Maryjayne's health blog.